Chen, Natalie Cheng et al. published their research in Leukemia & Lymphoma in 2021 | CAS: 1380087-89-7

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms was written by Chen, Natalie Cheng;Borthakur, Gautam;Pemmaraju, Naveen. And the article was included in Leukemia & Lymphoma in 2021.Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide This article mentions the following:

With improved understanding of the epigenetic alterations underlying cancer development, numerous novel agents targeting pathways involved in epigenetic modifications and transcription including bromodomain inhibitors are under active investigation. We aim to discuss epigenetic modulation with a focus on bromodomain extra-terminal inhibitors (BETi) in the treatment of myeloid neoplasms. Since the first proof-of-concept description of BETi synthesis and its antineoplastic effect, approx. 20 BETi have been generated and many of them are studied in the context of cancer treatment. Emerging pre-clin. and early clin. studies suggest that BETi may have activity in the management of many hematol. malignancies including acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), myeloproliferative neoplasm (MPNs), and lymphoma. We comprehensively reviewed and summarized preclin. and clin. data on BETi in treating myeloid neoplasms. In the experiment, the researchers used many compounds, for example, (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide).

(S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide (cas: 1380087-89-7) belongs to isoxazole derivatives. Isoxazoles present in various natural products and synthetic compounds of biological importance like antibacterial, antagonists, antiinflammatory, analgesics, and also show the applications in functional materials. Some alternative routes for the synthesis of isoxazoles have also been developed and reported. The 2-benzoyl-2-halo-2H-azirines provide 4-haloisoxazoles in good yields after heating in toluene at reflux temperature.Application In Synthesis of (S)-2-(6-(4-Chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem